The aim of the article is to capture the session at EuroPCR 2015, communicate the analysis of the trialists, and report the views expressed in the interactive discussion.
Introduction to the session
Bioresorbable stents (BRS) have been described as the fourth revolution in interventional cardiology. ABSORB II is the first randomised controlled clinical trial (RCT) comparing an everolimus-eluting BRS with a second-generation everolimus-eluting permanent metallic stent (DES)1. A dedicated interactive EuroPCR session subjected this study to focused scrutiny with the help of facilitators consisting of Ibrahim Al-Rashdan, Robert ...
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com